Related Experiment Video
Updated: May 7, 2025

11:52
Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations
Published on: August 4, 2016
10.3K
Gene Fusion Detection in Long-Read Transcriptome Datasets from Multiple Cancer Cell Lines.
Keigo Masuda1, Yoshiaki Sota2, Hideo Matsuda1
1Graduate School of Information Science and Technology, Osaka University, 565-0871 Suita, Osaka, Japan.
Frontiers in Bioscience (Landmark Edition)
|December 30, 2024
Summary
A new tool enhances fusion gene detection in long-read RNA sequencing, overcoming high error rates. This advancement improves cancer biomarker discovery using full-length transcript sequencing.
Area of Science:
- Genomics
- Cancer Research
- Bioinformatics
Background:
- Fusion genes are critical cancer biomarkers due to oncogenic abnormal proteins.
- Long-read RNA sequencing (long-read RNA-seq) enables full-length mRNA transcript sequencing for fusion gene detection.
- High error rates in long-read RNA-seq pose challenges for accurate fusion gene identification.
Purpose of the Study:
- To develop an improved tool for detecting fusion genes in long-read RNA sequencing data.
- To enhance the accuracy of fusion gene detection despite inherent sequencing errors.
Main Methods:
- Incorporated novel steps: breakpoint anchoring to exon boundaries, realignment of unaligned regions, and breakpoint clustering.
- Evaluated tool accuracy by comparing it against established tools like JAFFAL and FusionSeeker.
- Utilized long-read RNA sequencing datasets from cancer cell lines.
Main Results:
- The developed tool demonstrated superior performance in detecting fusion genes compared to JAFFAL and FusionSeeker.
- Identified potential novel fusion genes through consistent detection across multiple tools and datasets.
- Validated the tool's effectiveness on real-world cancer cell line data.
Conclusions:
- The new tool effectively detects fusion genes in long-read RNA sequencing data.
- This advancement aids in identifying crucial cancer biomarkers.
- The tool's performance was confirmed across different cancer cell line datasets.

